2m 2m 2m 2m 2m 2m 2m
IMMUNOME (IMNM)
NASDAQ
$19.00-$0.18 (-0.93%)
Price as of Jun 23, 2026 6:09 PM EDT- $2.2BMarket Cap
- 119.45%1-Year Change
- BiotechnologyIndustry
IMMUNOME (IMNM)
$19.00-$0.18 (-0.93%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 6.9M -23.23% | 9.0M -35.50% | 14.0M +280,260.00% | 5,000 +150.00% | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 6.9M -23.23% | 9.0M -35.50% | 14.0M +280,260.00% | 5,000 +150.00% | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -177.3M +36.86% | -129.5M +461.06% | -23.1M -0.79% | -23.3M +64.93% | |
Depreciation and Amortization Expense | 2.5M +57.37% | 1.6M +242.89% | 457,000 +8.29% | 422,000 -44.11% | |
Total Operating Expenses | 231.1M -26.61% | 314.8M +154.83% | 123.5M +234.81% | 36.9M +46.41% | |
Operating Profit | -224.1M -26.71% | -305.8M +179.19% | -109.5M +196.82% | -36.9M +46.41% | |
Interest Income | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 0 N/A | 0 N/A | 0 N/A | 0 +100.00% | |
Total Nonoperating Income and Expense | 11.7M -8.71% | 12.8M +371.26% | 2.7M +54,380.00% | 5,000 -98.99% | |
Income before Taxes | -212.4M -27.50% | -293.0M +174.29% | -106.8M +184.68% | -37.5M +48.86% | |
Income Taxes | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -212.4M -27.50% | -293.0M +174.29% | -106.8M +189.48% | -36.9M +49.31% | |
Net Income from Continuing Operations Applicable to Common | -212.4M -27.50% | -293.0M +174.29% | -106.8M +184.68% | -37.5M +51.83% | |
Basic EPS and Net Income | -2.43 -51.40% | -5.00 -7.06% | -5.38 +74.11% | -3.09 +44.39% | |
Diluted EPS and Net Income | -2.43 -51.40% | -5.00 -7.06% | -5.38 +74.11% | -3.09 +44.39% | |
Basic Weighted Average Shares | 87.4M +48.96% | 58.6M +195.51% | 19.8M +63.64% | 12.1M +5.10% | |
Diluted Weighted Average Shares | 87.4M +48.96% | 58.6M +195.51% | 19.8M +63.64% | 12.1M +5.10% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 653.5M +355.86% | 143.4M +45.27% | 98.7M +385.55% | 20.3M -58.72% | |
Short-Term Investments | 0 -100.00% | 74.0M +87.40% | 39.5M N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 653.5M +200.72% | 217.3M +57.30% | 138.1M +579.73% | 20.3M -58.72% | |
Total Current Assets | 660.8M +198.54% | 221.3M +52.96% | 144.7M +538.89% | 22.6M -60.01% | |
Accumulated Depreciation | 6.4M +34.13% | 4.7M +21.52% | 3.9M +13.24% | 3.5M +13.93% | |
Property and Plant and Equipment and Net | 14.6M +44.72% | 10.1M +387.84% | 2.1M +204.41% | 681,000 -20.35% | |
Total Long-Term Assets | 4.6M +3.99% | 4.4M +4,311.00% | 100,000 -90.13% | 1.0M -14.66% | |
Total Assets | 683.2M +184.38% | 240.2M +61.73% | 148.5M +517.73% | 24.0M -58.49% | |
Income Taxes Payable | 5.3M -4.18% | 5.6M +1,369.31% | 378,000 N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 45.0M -17.16% | 54.3M +148.78% | 21.8M +197.76% | 7.3M -24.64% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 3.9M -62.42% | 10.3M +665.52% | 1.3M +2,061.29% | 62,000 -57.53% | |
Total Liabilities | 48.8M -17.32% | 59.1M +106.14% | 28.7M +287.64% | 7.4M -24.10% | |
Retained Earnings | -728.2M +41.18% | -515.8M +131.49% | -222.8M +92.07% | -116.0M +46.64% | |
Total Stockholders Equity | 634.3M +250.15% | 181.2M +51.12% | 119.9M +619.88% | 16.7M -65.44% | |
Total Shares Outstanding | 113.1M +75.51% | 64.5M +49.04% | 43.3M +256.60% | 12.1M +0.15% | |
Cash Flow | |||||
Cash from Operating Activities | -190.9M +72.32% | -110.8M +1,363.98% | -7.6M -73.62% | -28.7M +57.41% | |
Capital Expenditures | 9.7M +35.02% | 7.2M +763.18% | 831,000 +235.08% | 248,000 +213.92% | |
Cash from Investing Activities | 60.8M +171.48% | -85.1M +179.04% | -30.5M +12,191.94% | -248,000 +213.92% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 640.4M +166.23% | 240.5M +106.63% | 116.4M +363,675.00% | 32,000 -99.88% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | -3,228.83% -4.54% | -3,382.37% +332.89% | -781.35% -99.89% | -738,020.00% -392.82% | |
Return on Assets | -46.00% -69.48% | -150.71% +21.76% | -123.77% +37.49% | -90.02% +86.61% | |
Return on Equity | -52.09% -73.24% | -194.63% +24.40% | -156.45% +37.47% | -113.81% +106.17% | |
Revenue Growth | -23.23% -34.58% | -35.50% -100.01% | 280,260.00% +186,740.00% | 150.00% +103.57% | |
Current Ratio | 14.69 +260.36% | 4.08 -38.52% | 6.63 +114.56% | 3.09 -46.94% | |
Cash Ratio | 14.53 +450.28% | 2.64 -41.61% | 4.52 +63.07% | 2.77 -45.22% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow